Results 221 to 230 of about 5,780,328 (293)

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin   +11 more
wiley   +1 more source

Systematic scale-up and enhanced purification of marine cyanophage P-SSP7. [PDF]

open access: yesFront Microbiol
Bohutskyi P   +5 more
europepmc   +1 more source

AI-driven pilot platforms and computational pharmaceutics: accelerating innovation in small molecule drug development under industry 4.0 and 5.0 paradigms. [PDF]

open access: yesFront Pharmacol
Luo K   +12 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy